On October 21, 2026, Retension Pharmaceuticals appointed Robert Wong as Vice President, Chief Accounting Officer, effective November 2, 2026. Mr. Wong brings 30 years of management and controllership experience to the role
Who to call at Retension Pharmaceuticals, and when
A new leader at Retension Pharmaceuticals brings new priorities and often new vendors. The first weeks are when they listen.
An alert the day Retension Pharmaceuticals raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Retension Pharmaceuticals, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Retension Pharmaceuticals
About
Retension Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative therapies. The company aims to address unmet medical needs through its research and development efforts. Retension is committed to advancing healthcare through scientifically advanced solutions.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Retension Pharmaceuticals changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
